Rights and permissions
About this article
Cite this article
Bevacizumab + INF-α-2a: safer and therefore less costly in mRCC. Pharmacoecon. Outcomes News 617, 2 (2010). https://doi.org/10.2165/00151234-201006170-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201006170-00001